Clinical trial · Interventional
Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer
An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability, and Efficacy of Low Dose G-FLIP in Combination With Mitomycin C in Patients With Stage IV Pancreatic Cancer Who Have Failed First-Line Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study focuses on advanced metastatic pancreatic cancer, testing a combination of low-dose anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) with the addition of Mitomycin C. The aim is to find a safer and more effective therapy for this devastating disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| G-GLIP plus Mitomycin C | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- G-GLIP plus Mitomycin C
- description
- G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin every 2 weeks plus Mitomycin C every 4 weeks
- interventionNames
- Drug: G-GLIP plus Mitomycin C
Primary outcomes (2)
- measure
- Overall Survival
- timeFrame
- Baseline, 3 months, 6 months, 1 year, and then annually up to 5 years.
- description
- This measure assesses the duration of time from the start of the study until death from any cause.
- measure
- Response Rate
- timeFrame
- Baseline, 3 months, 6 months, 1 year, and then annually up to 5 years.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed metastatic (Stage IV) pancreatic adenocarcinoma. * Failed first-line chemotherapy. * ECOG performance status of 0-2. * Expected survival of more than 3 months. * Adequate organ function as indicated by lab values. * Age 18 or older. * Signed informed consent. Exclusion Criteria: * • Known brain metastases. * Significant cardiovascular or other uncontrolled diseases. * Pregnant or breastfeeding women
References
Publications (0)
Data not yet available